Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

CRWENewswire Presents Two Stocks To Watch for Sept 3, 2010 - HealthMed, HEME; StemCells, Inc, STEM

|Includes: Microbot Medical Inc (MBOT)

HealthMed Services LTD., (HEME.OB) is a development stage company, that intends to provide individuals, companies, and health-provider organizations with telephone and Web-based access to medical advice, information, and products and services in the United States and internationally.

HealthMed plans to offer outsourced services to clients through its Internet-based information and medical advice Web site, as well as through its proposed call center by supplying the tools, technology, and know-how required for the operation of a health information center. The company plans to provide online services through its Web site, which include public portal, a Web site for individuals, consumers, and the general public that is designed to provide health information and recommendations; and private and custom-designed/client specific portal, a private-labeled Web site that would allow employees to access their personal health records and research various health and medical related topics, as well as provide access to information and resources to assist them in making personal health plan and medical treatment decisions.

HealthMed also intends to offer health information services in various languages through call centers by telephone and Internet to payers, providers, and end-users of medical service in North America, Latin America, and Europe. The company was formerly known as Telemax Communications, Inc. and changed its name to HealthMed Services LTD. in July 2003. HealthMed Services LTD. was founded in 2000 and is based in Las Vegas, Nevada.

For More Information On HealthMed's Products and Services, Visit:

Last Trade: 0.165


StemCells, Inc. (Nasdaq:STEM) announced today that its technology was recently used by independent researchers to achieve the first genetically engineered rat derived from rat embryonic stem (NYSE:ES) cells. This breakthrough, published this month in the international peer-reviewed journal Nature, opens the door to the types of genetic manipulations previously only possible in mice, and paves the way for modeling a broader range of human diseases with the rat. Both mice and rats are used as animal models of human disease; however certain aspects of the rat's physiology, behavior, and metabolism are closer to the human, making rats the preferred species for drug development and studying human disease. The creation of this first rat model using rat ES cells validates intellectual property owned by StemCells, which includes the rights to patents covering both rat ES and rat induced pluripotent stem (iPS) cells as well as genetically engineered rats derived from these cells.

Dr's at USC demonstrated for the first time the creation of genetically modified rats using rat ES cells that have been gene targeted via homologous recombination, a method which involves adding DNA sequences to the cells to delete ('knock-out'), add ('knock-in') or otherwise modify genes of interest. This latest work resulted in the successful generation of knock-out rats missing the tumor suppressor gene p53 for use in studying cancer, and serves as a proof-of-principle for creating genetically engineered rats using rat ES cells. The rat ES cells used to generate the genetically engineered rats were cultured using a special '2i' inhibitor-based media formulation. This proprietary 2i media is exclusively licensed to StemCells, Inc. and marketed as GS1-R(NYSE:TM). GS1-R is part of the Company's SC Proven(NYSE:R) line of specialty cell culture products, and is the first and only commercially available medium shown to enable the derivation and long-term maintenance of the true rat ES cells required for precise genetic manipulation. For more information about GS1-R and the Company's other SC Proven(R) specialty cell culture products, interested parties are invited to visit

StemCells, Inc. is engaged in the research, development, and commercialization of stem cell therapeutics and tools for use in stem cell-based research and drug discovery. In its therapeutic product development programs, StemCells is targeting diseases of the central nervous system and liver.

Last Trade: 0.78

Volume: 18,590

Change: 0.65%


The Views and Opinions Expressed by the author are his or her opinions only and do not necessarily reflect those of this Web-Site or its agents, affiliates, officers, directors, staff, or contractors. The author at the time of this article did not own any shares or receive any consideration financial or otherwise from any company or person mentioned or referred to in the article.


Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period. (OTCPK:CRWE) has received five thousand dollars in cash from a third party (Media Elite Consultants LLC) for (1) day of advertising for Healthmed Services Ltd. (OTC BB: HEME.OB)